Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1996;94:1894-1901

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nascimben, L.
Right arrow Articles by Allen, P.D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nascimben, L.
Right arrow Articles by Allen, P.D.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Heart Failure

(Circulation. 1996;94:1894-1901.)
© 1996 American Heart Association, Inc.


Articles

Creatine Kinase System in Failing and Nonfailing Human Myocardium

Luigino Nascimben, MD; Joanne S. Ingwall, PhD; Paolo Pauletto, MD; Jan Friedrich, DPhil; Judith K. Gwathmey, VMD, PhD; Valdur Saks, PhD; Achille Cesare Pessina, MD, PhD; P.D. Allen, MD, PhD

the NMR Laboratory for Physiological Chemistry, Cardiovascular Division, Department of Medicine (L.N., J.S.I., J.F.) and Department of Anesthesia (P.D.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, Mass; Istituto di Medicina Clinica, Universita di Padova (Italy) (L.N., P.P., A.C.P.); Cardiovascular Disease and Muscle Research Laboratories, Department of Medicine, Beth Israel Hospital and Department of Cellular and Molecular Physiology, Harvard Medical School, Boston, Mass (J.K.G.); and Laboratory of Bioenergetics, Research Center for Cardiology, Moscow, Russia (V.S.).

Correspondence to Luigino Nascimben, MD, NMR Laboratory for Physiological Chemistry, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115. E-mail luigin@bustoff.bwh.harvard.edu.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background The creatine kinase (CK) reaction is important for rapid resynthesis of ATP when the heart increases its work. Studies defining the CK system in human failing and nonfailing myocardium are limited and in conflict. To resolve this conflict, we measured the activities of CK and its isoenzymes and the contents of creatine and CK-B in homogenates of human myocardium.

Methods and Results Myocardium was sampled from 23 subjects who underwent heart transplant, 36 subjects maintained in an intensive care unit before heart harvesting, 13 accident victims, and 2 patients undergoing heart surgery. Since the characteristics of myocardium of potential organ donors differed from those of myocardium of accident victims, data are presented for three groups: failing, donor, and control. CK activity was 7.7±1.9 and 6.0±1.4 IU/mg protein in left (LV) and right (RV) ventricles of failing, 9.4±2.5 and 10.7±2 IU/mg protein in LV and RV of donor, and 11.6±2.4 IU/mg protein in LV of control hearts. CK-MM and the mitochondrial isoenzyme activities were lower in failing and donor LV, and CK-MB activity and CK-B content were higher in failing and donor hearts. Creatine contents were 64±25 and 56±18.6 nmol/mg protein in LV and RV of failing, 96±30 and 110±24 nmol/mg protein in LV and RV of donor, and 131±28 nmol/mg protein in LV of control hearts.

Conclusions In failing and nonfailing donor human myocardium, there is a combined decrease of CK activity and creatine that may impair the ability to deliver ATP to energy-consuming systems.


Key Words: heart failure • cardiomyopathy • creatine kinase • creatine • transplantation


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Patients with DCM exhibit progressive heart failure with extensive dilation and decreased systolic function. An early clinical sign of heart failure is a diminished tolerance for exercise. The cause and pathogenesis of heart failure have not yet been clearly defined, although many hypotheses have been proposed. Among them, the hypothesis that failing myocardium is energy depleted is gaining renewed interest.1 2

In hearts of several animal models of heart failure, it has been shown that the maximal velocity of the CK reaction is decreased, the relative distribution of CK isoenzymes is changed, and the contents of the substrates and products of the CK reaction, namely ATP and PCr, are decreased.3 4 5 6 7 Isolated perfused hearts of these animals perform less cardiac work. The importance of CK for normal contractile performance of muscle has been demonstrated in experiments designed to alter the CK reaction by either inhibiting CK activity or decreasing the concentration of creatine. The ability of hearts to increase their contractile performance is reduced when myocardial creatine is replaced with poorly hydrolyzable creatine analogues8 or when CK activity is acutely inhibited with sulfhydryl group modifiers.9 Langendorff-perfused failing hearts of cardiomyopathic hamsters and turkeys have been shown to have lower total creatine content and CK activity and to perform less cardiac work.5 6 In these failing hearts, both the total CK activity measured in vitro and the CK reaction velocity directly measured in vivo by 31P magnetization transfer were decreased. Experiments using animal models have also demonstrated that CK activity and creatine content combine to determine the capacity for resynthesizing ATP via the CK reaction and that the integrity of this pathway for ATP resynthesis is required for the recruitment of the functional reserve of heart.6 7 8 9 Finally, in support of these observations, it has been shown that skeletal muscle from mice that are homozygous for a "knockout" of the CK-M gene is unable to perform burst work.10

At present, characterizations of the CK system in human failing and nonfailing myocardium are incomplete and not in full agreement. Decreased total CK activity in subjects with DCM has been reported by our group in abstract form11 and by Sylven et al.12 Bristow et al,13 in contrast, have suggested that the total CK activities in donor and failing hearts were not different. Several groups using in vivo 31P NMR spectroscopy have demonstrated that the PCr/ATP ratio is lower in failing human myocardium,14 15 16 but PCr and ATP contents have not been determined. The creatine content of failing human myocardium has not been reported. Moreover, variables such as age, disease progression, drug therapy, regional myocardial heterogeneity, and overall heterogeneity of the population may complicate the interpretation of data for both normal and failing myocardium.

The objective of this study was to define and compare the CK systems in subjects who had heart failure due to end-stage DCM with those in subjects who had normal heart function. Subjects with normal heart function included both organ donors and accident victims. We measured the creatine content, the total CK activity, and the CK isoenzyme distribution in specimens of LV myocardium obtained at the time of surgery or autopsy. In a subset of failing and organ donor subjects, we also tested for any chamber differences. By making conservative assumptions about the fraction of the creatine pool that is phosphorylated combined with literature values for changes in ATP content in DCM hearts, we also estimated CK reaction velocity in failing and nonfailing human myocardium.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Subjects
Samples of human myocardium were obtained from the LV of subjects undergoing open-heart surgery for repair of mitral stenosis or atrial septal defect who had normal ventricular function (n=2), accident victims at autopsy within 3 hours of death (n=13), donor subjects at the time of organ harvesting or transplantation (n=36), and patients with DCM who underwent heart transplantation (n=23).

The subjects were divided into three groups. The control group (n=15) included the normal surgical and autopsy samples (mean age, 29.6±10.3 years; range, 17 to 53 years). Results from 9 of these subjects have been reported previously.17 The heart donor group included subjects who had no known heart disease but who had been maintained on life support treatment for 24 to 120 hours before heart harvesting (mean age, 34.4±15.9 years; range, 16 to 65 years). The heart failure group consisted of patients with DCM whose hearts were sampled at the time of cardiac transplantation (mean age, 37.2±9.0 years; range, 15 to 54 years). There were no age differences among groups. All but 2 subjects in the donor group and 1 in each of the other two groups were men.

We also collected samples from the free walls of the LA, RA, and RV from a subset of the subjects in the donor (n=6) and failure (n=17) groups for an analysis of possible regional differences.

Immediately after removal, all myocardial samples were frozen in liquid nitrogen and stored frozen until use.

Biochemical Analysis
Portions of the myocardial biopsy specimens (5 to 20 mg) were cut from frozen samples, weighed, and analyzed as previously described5 6 17 for noncollagen protein, CK-B content, total creatine content (PCr plus free creatine), total CK and CS activities, and the relative distribution of the CK isoenzymes (BB, MB, MM, and mitochondrial). Since the specific activities of the CK isoenzymes are similar,18 relative activities can be estimated by multiplying the relative concentrations by total CK activity.

The study design was independently approved before the study began by the Ethics Committee for Organ Transplant, University of Padova Hospital, and the Committee for the Protection of Human Subjects, Brigham and Women's Hospital, Boston, Mass.

Data Analysis
Normalizing substrates and enzyme activities by Lowry protein content minimizes the contributions of edema, fibrosis, and any change of interstitial water that could have confounding effects on enzyme and substrate concentrations. This is because extracellular proteins contain relatively low amounts of aromatic amino acids, the target for the Lowry assay. Accordingly, in this report, enzyme activities and creatine and CK-B contents were normalized to Lowry protein to better reflect the mass of viable myocytes.

We estimated the forward velocity (Vfor) of the CK reaction in myocardium in vivo in two ways. Both methods are based on the rate equation developed to determine the velocity of the CK reaction for CK-MM in solution.19 The rate equation is

(E1)
where Vmax is the total CK activity measured under saturating conditions; D, ka, and kib are kinetic constants calculated from values from References 19 and 20; and ADP concentration is calculated from the CK equilibrium expression

(E2)
For the first method, we used the rate equation directly and entered the values for Vmax and the substrates for the CK reaction into Equation 1. To convert substrate amounts and enzyme activities to cytosolic concentrations, we assumed that the cytosolic volume of blood-perfused myocardium is 0.65 mL/g wet wt21 and used the ratio of mg protein per wet weight that we measured for each group. Vmax at 37°C was obtained by multiplying our measured values of CK activity measured at 30°C by 1.8, a value we determined experimentally using pure CK-MM. We used [ATP] obtained by 31P NMR spectroscopy of healthy volunteers22 for the control group. Since Regitz and Fleck23 reported that ATP content expressed as nmol/mg protein was the same for control and failing myocardium, we scaled the [ATP] for differences in noncollagen protein content of donor and failing groups. [PCr] and [free creatine] were obtained under the assumption that 65% of the total creatine pool was phosphorylated. [ADP] was calculated from these values and the CK equilibrium equation (Equation 2), with a pH of 7.11.

The validity of these assumptions was tested by comparison of results for the PCr/ATP ratio determined in this way with results obtained by Neubauer et al,16 who studied normal, healthy subjects and DCM patients by 31P NMR spectroscopy. Our calculated values of PCr/ATP of 2.0 for control and 1.0 for failing groups compare favorably to values of 2.0±0.4 for healthy volunteers and 1.4±0.5 for DCM patients classified as New York Heart Association class III to IV. It is noteworthy that three of the four patients in class III to IV of that study had a PCr/ATP ratio of {approx}1.0, similar to the patients in the failing group (all class IV) described here.

In the second method, we estimated the relative changes in CK reaction velocity by considering only the numerator of the rate equation.7 By multiplying Vmax by the total creatine pool, we obtain an estimate of the maximal capacity to resynthesize ATP via the CK reaction under conditions in which substrate availability is not limiting. This estimate is based on our observations that, of the parameters in the numerator of Equation 1, Vmax and creatine (which is proportional to PCr) vary more than the adenylate pool (which is proportional to ADP) in DCM.5

Data are expressed as mean±SD. Comparisons were made by use of statistical software (Systat 5.2.1, Systat Inc, and Statview, TM 512+, Brainpower Inc). To compare results of the tests among three groups of ventricles, one-way factorial ANOVA and Tukey's highly significant difference post hoc test for multiple comparisons were used. In the regional analysis, for which samples of only two groups were available, a two-tailed unpaired Student's t test was applied to compare sections of two different groups and a two-tailed paired Student's t test to compare two sections of the same heart. A value of P=.05 was considered statistically significant. To correlate CK-MM activity with creatine content and CK-MB activity with CK-B content, we used linear regression analysis.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
CK Activity in the LV of Failing and Nonfailing Hearts
Values for total CK activity, CK isoenzyme distribution, and total creatine content of the LV for the three groups are summarized in Table 1Down. Individual data are shown in Figs 1Down and 2. The content of noncollagen protein per milligram wet weight of control myocardium (0.16±0.02) was higher than that of donor myocardium (0.13±0.03, P<.001) and failing myocardium (0.12±0.02, P<.001). Because we normalized results to protein content, which was higher in the control group, we minimized any differences that could have been attributed to edema and fibrosis.


View this table:
[in this window]
[in a new window]
 
Table 1. CK System in LVs



View larger version (15K):
[in this window]
[in a new window]
 
Figure 1. Total creatine (A) and total CK activities (B) in myocardium of LVs of control, donor, and failing hearts. {bullet} represents subjects with heart failure; {triangleup}, heart donors; {blacksquare}, accident victims; and {square}, two subjects who underwent heart surgery. For the statistical comparisons, these two data points were added to the accident victims to form the control group. I bars represent mean±SD. P values indicate probability that the group means are not different.

Myocardium from failing hearts contained less creatine than myocardium of control hearts (-50%, P<.001) and donor hearts (-26%, P<.001). It also contained less total CK activity than myocardium from control hearts (-34%, P<.0005) and from donor hearts (-18%, P<.005). Therefore, failing myocardium contains less total creatine and less total CK activity than both groups of nonfailing hearts.

Myocardium from donor hearts contained less total creatine (-26%, P<.005) and less total CK (-19%, P<.05) activity than myocardium from control hearts.

Table 2Down shows estimates for the cytosolic concentrations of the substrates of the CK reaction and for the CK reaction velocity. The velocity of the CK reaction estimated from the rate equation was decreased in myocardium of failing hearts compared with both control and donor hearts (-56%, P<.0005, and -26%, P<.05, respectively) and was also decreased in donor hearts compared with controls (-40%, P<.0005).


View this table:
[in this window]
[in a new window]
 
Table 2. Cytosolic Concentrations of CK and Its Substrates and Estimates for the CK Reaction Velocity

CK Isoenzyme Distribution in the LV
The CK isoenzyme distribution, whether expressed as IU/mg protein or as percentage of the total activity, differed in myocardium of both failing and donor hearts compared with controls. Compared with the control group, mito-CK activity was decreased 45% (P<.001) in both failing and donor groups, CK-MM activity was 50% less in the failure group (P<.0005) and 32% less in the donor group (P<.0005), and CK-MB activity was increased about sevenfold in both the failure and donor groups (P<.0005). Fig 2Down shows that the lower total CK activity of failing and donor myocardium is primarily a result of a decrease in CK-MM activity and, to a lesser extent, of a decrease in mito-CK activity. The increase in CK-MB in the myocardium of the LVs in both of these groups was insufficient to maintain normal total CK activity. The BB isoenzyme was detected in only some samples: 1 normal subject (3.5% of his total CK), 14 (of 36) donors (<2% of total CK on average), and 2 DCM subjects (<1% of total CK on average).



View larger version (11K):
[in this window]
[in a new window]
 
Figure 2. The distribution of CK isoenzymes CK-MB ({blacksquare}), CK-MM ({bullet}), and mito-CK ({triangleup}) in myocardium from LVs of control, organ donor, and failing subjects. {square} indicates the two subjects who underwent heart surgery. I bars represent mean±SD.

The percentage of the CK-MB isoenzyme activity was higher in the failure group (27.3%) than in the control (2.4%, P<.0005) and donor groups (19.7%, P<.0005). This is only partially due to the decrease of CK-MM and mito-CK isoenzymes. When CK-B was quantified directly by use of an antibody specific to CK-B, CK-B content per milligram protein was 10 times higher in the failure group (P<.0005) and 12 times higher in the donor group (P<.0005) than in the control group. Fig 3ADown shows the relationship between CK-B content per milligram protein and CK-MB activity in the ventricles. There is a strong correlation between MB activity and CK-B content in the control group (y=-0.01+0.43x, r=.98, P<.001) and in the failure group (y=-0.02+0.48x, r=.87, P<.001). Interestingly, there was a weaker correlation of these two variables in the donor group (y=0.36+0.44x, r=.70, P<.05). These relationships provide information about the specific activity of the B-containing CK isoenzymes in the three groups and also about the fraction of the CK-MB that is active. The specific activity of CK-MB (the inverse of the slopes) in all groups is the same, making it likely that the same protein accumulated regardless of pathology. For the control and failure groups, the y intercept was not different from zero, showing that all of the active B-containing enzyme was detected by the antibody. This was not the case in the donor group. For this group, antibody detected inactive B monomer.



View larger version (18K):
[in this window]
[in a new window]
 
Figure 3. Plot of CK-MB isoenzyme (MB-CK) against CK-B protein in LVs (A) and left and right atria (B) with regression lines. A, {blacksquare} indicates control (y=-0.009+0.43x; r=.97); {triangleup}, organ donor (y=0.36+0.44x; r=.70); and {bullet}, heart failure (y=-0.02+0.48x, r=.81). B, {triangleup} indicates organ donor (y=0.004+0.53x; r=.92); {bullet}, heart failure (y=0.6+0.55x; r=.93). The shift of the regression lines of the organ donor group in both atria and ventricles indicates that some of the CK-B monomer detected by the antibody is inactive.

Fig 4Down shows the relationship between total creatine content (the substrate) and CK-MM activity (the dominant enzyme) by use of the data points from all the regions of the heart and from all three groups. There is a significant relationship between CK-MM activity and the total creatine content (y=1.9+0.05x, r=.80, P<.0001). There was a weaker correlation between mito-CK activity and total creatine content (y=0.21+0.006x, r=.44, P<.0001) and no correlation between total creatine content and CK-MB.



View larger version (16K):
[in this window]
[in a new window]
 
Figure 4. Graph showing the relation between the content of total creatine and the activity of the MM isoenzyme of creatine kinase (CK-MM). The three groups include all the samples from left ventricles of the control group and from the atria and the ventricles of the failing and organ donor groups. {blacksquare} indicates control (n=15); {triangleup}, organ donor (n=54); and {bullet}, heart failure (n=74). Regression line: y=1.9+0.05x; r=.80.

Regional Characteristics of CK System in Failing and Donor Hearts
Table 3Down presents the results of the biochemical assays for RV, LA, and RA in subgroups of the donor and failing hearts. RV, LA, and RA from the donor and failure groups contained a similar amount of noncollagen protein per milligram wet weight, which was not different from what was found in their LVs.


View this table:
[in this window]
[in a new window]
 
Table 3. CK System in Myocardium of RVs and Atria of Donor and Failing Groups

As was found in the LV, the total creatine content and total CK activity in the RV of the failure group were lower (-49% and -39%, respectively) than in the RV of the donor group. Likewise, CK-MM and mito-CK activities were decreased (-50% and -70%, respectively) in the RV of the failure group compared with the donor group.

Total creatine content and total CK activity in LA and RA were lower than in their respective ventricles for both groups (compare Table 3Up and Table 1Up). There were no differences between LA and RA of either group or between atria in donor and failing groups. CK-MM and CK-MB activities were also not different between the two groups, but mito-CK activity was 65% lower in the failure group than in the donor group. Myocardium from the RV and from both atria of donor hearts contained about 50% and 40% more CK-B protein than myocardium from failing hearts, respectively. Fig 3BUp shows the relationship between the content of CK-B protein and CK-MB enzyme activity for all atrial samples in the donor and failure groups. As was seen in the LV, the higher CK-B content in the donor hearts was not accompanied by a comparable increase in CK-MB activity.

Mitochondrial Enzyme Activities by Region and by Group
Changes of mito-CK could reflect either a specific reduction in the amount of the mito-CK activity in otherwise normal mitochondria or a nonspecific decrease in the fractional cell volume of mitochondria. To distinguish between these possibilities, we also measured the activity of CS, which is proportional to mitochondrial cell volume, and calculated the ratio of mito-CK to CS activities for the LV of all three groups and the RV, LA, and RA of the donor and the failing groups. Values for the LV were the same for all three groups (0.49±0.12, 0.45±0.11, and 0.48±0.09 IU/mg protein, P=NS) and were indistinguishable from values for RV of the donor and failing groups (0.47±0.05 and 0.44±0.06 IU/mg protein, respectively). Atria of donor hearts contained the same CS activity (0.48±0.06 IU/mg protein for both LA and RA) as the ventricles. However, CS activity in the LA (0.36±0.09 IU/mg protein) and RA (0.35±0.09 IU/mg protein) of failing hearts was lower than in atria of the donor group (P<.005) and in ventricles of the failing group (P<.005).

Taking into account possible differences in the fractional cell volume of mitochondria as estimated by CS activity, the calculated mito-CK/CS ratio was lower in ventricles of failing (1.4±0.6) and donor (1.4±0.7) myocardium compared with controls (2.2±1.1, P<.05) (Table 1Up). This shows that the relative concentration of mito-CK on the mitochondria is lower in failing and donor hearts. There were no regional differences in this ratio for either the donor or the failing group (Table 3Up).


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
Total Creatine Content and Total CK Activity in Failing Hearts
In this study, we found that the creatine pool is decreased in all four chambers of the failing human myocardium. Ventricles but not atria from the failing hearts also have a lower total CK activity. The consequence of a decreased substrate pool coupled with a decreased enzyme activity is a reduction in the capacity of the CK system to synthesize ATP when there is an increased workload. We suggest that the decreased capacity to resynthesize ATP in the failing heart be described as decreased energy reserve. It is important to emphasize that, on the basis of known reaction kinetics, the effect of decreases in both substrate and enzyme activities on the capacity of the CK reaction is not just additive but rather multiplicative. The product of Vmax and total creatine pool was highest for control and lowest for failing hearts. This result was confirmed by calculating CK reaction velocity from the rate equation.

Our data showing decreased total creatine in failing hearts are supported by 31P NMR spectroscopy findings that the in vivo PCr/ATP ratio is 25% lower in failing human hearts14 15 16 than in healthy subjects. Because CK functions to maintain a constant PCr/creatine ratio, we would expect that our finding of a 50% decrease in creatine would be accompanied by a 50% decrease in PCr concentration. To reconcile this prediction with the NMR observations would require that the ATP pool also be depleted. A reduction in cytosolic ATP concentration in failing hearts has been observed both in human24 and in animal models,5 6 and the magnitude of the decrease is sufficient to reconcile these results. The results presented in the present study (Table 2Up) are in accord with these observations.

Our results showing decreased total CK activity are in good agreement with the reports of Sylven et al12 comparing hearts from patients with DCM and heart donors. They found that CK activity in the LV of failing hearts was 44% lower, whereas we found a 34% decrease. Bristow et al13 reported that CK activity in the LV from patients with DCM was 25% lower than for heart donors. They attributed this difference to a lower age of some subjects in the donor group; however, the mean age difference (5 years) was not significant. Although CK activity may well be decreased by aging, our results in subjects >14 years of age show that the decrease seen in DCM is primarily due to pathology.

The importance of the decreases in the creatine pool and in CK activity on myocardial energetics can be explained by analysis of the role of the CK system in excitable tissues. Because ATP resynthesis via the CK reaction is an order of magnitude faster than ATP synthesis via oxidative phosphorylation,20 the CK system guarantees constant ATP levels. This is especially important for the myocardium, in which ATP turnover rates are high even at baseline and can be rapidly increased more than fivefold under conditions of increased workload, such as occurs with exercise. Because the CK activity under saturating conditions determines the Vmax of the CK reaction and the total creatine content sets the amount of PCr (as well as free creatine) that is available for the CK reaction, they combine to determine the maximal capacity of ATP resynthesis through the CK reaction. Our results suggest that the capacity for ATP resynthesis via the CK system is 83% lower for failing myocardium than for control myocardium (Table 2Up). They also show that the decreases in creatine content and CK activity (in particular CK-MM) are coordinate (Fig 4Up).

Changes in the CK Activity and Creatine Content in Donor Hearts
A surprising finding of this report is that myocardium of heart donors has a lower creatine pool and lower CK activity than does myocardium obtained from the LVs of healthy accident victims. We cannot fully explain this finding, but it seems possible that the clinical conditions in which the subjects were maintained before heart harvesting had an effect on both the expression of CK isoenzymes in the myocardium and the size of the creatine pool. These subjects were mechanically ventilated and maintained under intensive life support treatment while in a coma for 24 to 120 hours. Subjects maintained on life support after a traumatic event have increased production of stress hormones and receive multiple drugs before organ harvest. Several observations in human and animal models of disease support the hypothesis that an increased adrenergic drive can modulate the contents of creatine and CK in the heart. Cultures of adult rat cardiac muscle cells25 and isolated perfused rat hearts26 lose CK when norepinephrine is supplied. Interestingly, these changes can be prevented with pretreatment with parasympathetic cholinergic agents.26 Turkeys with furazolidone-induced cardiomyopathy also have a decreased creatine content and a decreased total CK activity, which are prevented by long-term oral administration of propranolol and atenolol.27 Most importantly, human heart failure is characterized by activation of the sympathetic nervous system, and it has been found that the serum level of catecholamines correlates with the degree of heart failure.28

CK Isoenzyme Distribution
Among the many physiological and metabolic changes associated with myocardial development are progressive increases of PCr (and creatine) content, increased synthesis of CK-M and mito-CK, and a relative decrease in CK-B. With the development of cardiac hypertrophy and evolution to failure, an opposite pattern takes place, with a decrease in the size of the creatine pool and a decrease in the expression of CK-M and usually an increase in the expression of CK-B. It is still unclear whether the increase of CK-B is part of a general reexpression of immature-type proteins such as is seen with troponin T29 or whether it reflects a specific adaptive change to utilize PCr more effectively. If the latter, this would be especially important in DCM, in which the size of the creatine pool is decreased. The lower Km of the MB isoenzyme compared with CK-MM indicates a higher affinity for the substrates of the reaction30 and supports the hypothesis of an adaptive change.

We previously described an increase in the content of CK-B (usually seen as an increase in CK-MB) in the myocardium of several animal models of cardiac hypertrophy and failure2 and in human myocardium of subjects with LV hypertrophy, coronary artery disease, and mitral regurgitation.17 This observation has been confirmed by others.12 31 32 33 34 The data presented here support the hypothesis that the synthesis of CK-B also increases in the failing human myocardium. Our data also show large variability of the content of CK-MB in all groups (ranges are 0% to 16%, 5.2% to 31%, and 13.5% to 37.1% for control, donor, and failure groups, respectively).

The increase of CK-B and the decrease of CK-M and mito-CK in donor hearts suggest the existence of rapid mechanisms for regulation of synthesis of CK isoenzymes. A rapid increase in expression of CK-B has also been reported in the dog heart upon coronary artery occlusion34 and in the rat uterus in response to estrogens.35 CK-M mRNA decreased 40% in myocardium of dogs and rabbits33 within 2 hours after either coronary ligation or heat stress.

The variability of CK-B content in human myocardium and its rapid modulation suggest that CK-B expression may be mediated by one of the local or systemic neurohormonal factors that are activated during stress conditions. In support of this hypothesis, our data show that in both atria and ventricles of donor hearts, the amount of CK-B exceeds the amount predicted by the activity of CK-MB and CK-BB. Since it is unlikely that the CK-B antibody cross-reacts with some other protein only in the donor group, it is likely that these hearts synthesize an excess of CK-B and that the assembly into an active CK enzyme is not complete.

Mito-CK has been reported to be decreased3 or unchanged5 in animal models of DCM. We found decreased mito-CK activity in LV of failing and donor hearts compared with controls. This decrease is not a result of loss in mitochondrial mass, because the activity of CS, another mitochondrial protein, is the same in all groups. In contrast to these results for ventricular tissue, the mito-CK/CS ratio is similar in failing and donor atria, suggesting that the fractional cell volume of mitochondria of failing atria is decreased.

Clinical Implications
The results presented here from a study of human myocardium suggest that the failing heart is "energy starved,"1 at least with respect to its capacity to resynthesize ATP via the CK system. On the basis of experiments using animal models showing a relationship between energy reserve via the CK system and contractile reserve of both heart and skeletal muscles,6 7 8 9 it seems likely that the decreased energy reserve of the human failing heart has a similar functional correlate. Decreased ability to rapidly resynthesize ATP would be particularly important under conditions of acute increases in workload. Thus, decreased energy reserve may explain, at least in part, the decreased ability of DCM patients to exercise.

Our data also suggest that the information collected from the myocardium of organ donors, at least as it relates to the CK system, may not be representative of a population of healthy subjects. This conclusion may also apply to other biochemical systems measured in hearts of organ donors.

We do not know whether the loss of either CK activity or creatine content in the failing or donor hearts is an irreversible process. Moreover, it is not known whether the loss of CK and creatine has an impact on the outcome of the transplant or the functional capacity of the recipient patients. We can speculate, however, that any pharmacological or other intervention that maintains the capacity of the CK system in the organ donors by decreasing the loss of creatine content and CK activity would be beneficial.

Study Limitations
First, clinical characterization of the organ donors and accident victims is incomplete with respect to hemodynamic parameters and functional capacity. This limits our ability to relate biochemical and functional parameters. Second, it is possible that drugs that were administered to either the failing or donor subjects could have modulated the expression of the CK isoenzymes. Our study groups are too small to identify any specific interactions. Finally, the mechanisms that determine the biochemical remodeling of the CK system in failing and donor hearts remain to be elucidated.


*    Selected Abbreviations and Acronyms
 
CK = creatine kinase
CS = citrate synthase
DCM = dilated cardiomyopathy
LA = left atrium
LV = left ventricular, left ventricle
mito-CK = mitochondrial CK
PCr = phosphocreatine
RA = right atrium
RV = right ventricle


*    Acknowledgments
 
This study was supported in part by National Institutes of Health grant HL-52320. Dr Nascimben was a recipient of a fellowship award from Merck Sharp & Dohme Italy Spa. The authors thank Ilana Reis, MSc, and Martha Kramer, PhD, for technical assistance; the surgeons and the pathologists of the Cardiothoracic Departments of Brigham and Women's Hospital, Boston, Mass; Padova University Hospital, Italy; and NDRI for their cooperation during the collection of the samples; and Helena Laboratories, Beaumont, Tex, for technical assistance and for the use of a Cardio-Rep Instrument for automated electrophoretic analysis.


*    Footnotes
 
Presented in part at the 66th Scientific Sessions of the American Heart Association, Atlanta, Ga, November 8-11, 1993.

Received January 18, 1996; revision received April 18, 1996; accepted May 1, 1996.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Katz AM. Energetics and the failing heart. Hosp Pract. 1991;26:78-90.

2. Ingwall JS. Is cardiac failure a consequence of decreased energy reserve? Circulation. 1993;87(suppl VII):VII-58-VII-62.

3. Khuchua ZA, Ventura-Clapier R, Kuznetsov AV, Grishin MN, Saks VA. Alterations in the creatine kinase system in the myocardium of cardiomyopathic hamsters. Biochem Biophys Res Commun. 1989;165:748-757.[Medline] [Order article via Infotrieve]

4. Neubauer S, Horn M, Naumann A, Tian R, Hu K, Laser M, Friedrich J, Gaudron P, Schnackerz K, Ingwall JS, Ertl G. Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction. J Clin Invest. 1995;95:1092-1100.

5. Nascimben L, Friedrich J, Liao R, Pauletto P, Pessina AC, Ingwall JS. Enalapril treatment increases cardiac performance and energy reserve via the creatine kinase reaction in myocardium of Syrian myopathic hamsters with advanced heart failure. Circulation. 1995;91:1824-1833.[Abstract/Free Full Text]

6. Liao R, Nascimben L, Friedrich J, Gwathmey JK, Ingwall JS. Decreased energy reserve in an animal model of dilated cardiomyopathy. Circ Res. 1996;78:893-902.[Abstract/Free Full Text]

7. Tian R, Nascimben L, Daouk R, Ingwall JS. Depletion of energy reserve via creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. J Mol Cell Cardiol. 1996;28:755-765.[Medline] [Order article via Infotrieve]

8. Zweier JL, Jacobus WE, Korecky B, Brandejs-Barry Y. Bioenergetic consequences of cardiac phosphocreatine depletion induced by creatine analogue feeding. J Biol Chem. 1991;266:20296-20304.[Abstract/Free Full Text]

9. Hamman BL, Bittl JA, Jacobus WE, Allen PD, Spencer RS, Tian R, Ingwall JS. Inhibition of the creatine kinase reaction decreases the contractile reserve of the isolated rat heart. Am J Physiol. 1995;269:H1030-H1036.[Abstract/Free Full Text]

10. van Deursen J, Heerschap A, Oerlemans F, Ruitenbeek W, Jap P, ter Laak H, Wieringa B. Skeletal muscles of mice deficient in muscle creatine kinase lack burst activity. Cell. 1993;74:621-631.[Medline] [Order article via Infotrieve]

11. Nascimben L, Pauletto P, Pessina AC, Reis I, Ingwall JS. Decreased energy reserve may cause pump failure in human dilated cardiomyopathy. Circulation. 1991;84(suppl II):II-563. Abstract.

12. Sylven C, Lin L, Jansson E, Sotonyi P, Fu LX, Waagstein F, Hjalmarsson A, Marcus C, Bronnegard M. Ventricular adenine nucleotide translocator mRNA is upregulated in dilated cardiomyopathy. Cardiovasc Res. 1993;27:1295-1299.[Medline] [Order article via Infotrieve]

13. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J, Feldman AM. Differences in ß-adrenergic neuroeffector mechanism in ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:1024-1039.[Abstract/Free Full Text]

14. Conway MA, Allis J, Ouwerkerk R, Nhoka T, Rajagopalan B, Radda GK. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet. 1991;338:973-976.[Medline] [Order article via Infotrieve]

15. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J. 1991;122:795-801.[Medline] [Order article via Infotrieve]

16. Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GAJ, Lackner K, Ertl G. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease: altered cardiac high-energy phosphate metabolism in heart failure. Circulation. 1992;86:1810-1818.[Abstract/Free Full Text]

17. Ingwall JS, Kramer MF, Fifer MA, Lorell BH, Shemin R, Grossman W, Allen PD. The creatine kinase system in normal and diseased human myocardium. N Engl J Med. 1985;313:1050-1054.[Abstract]

18. Basson CT, Grace AM, Roberts R. Enzyme kinetics of a highly purified mitochondrial creatine kinase in comparison with cytosolic forms. Mol Cell Biochem. 1985;67:151-159.[Medline] [Order article via Infotrieve]

19. Morrison JF, Cleland WW. Isotope exchange studies of the mechanism of the reaction catalyzed by adenosine triphosphate: creatine phosphotransferase. J Biol Chem. 1966;241:673-683.[Abstract/Free Full Text]

20. Bittl JA, DeLayre J, Ingwall JS. Rate equation for creatine kinase predicts the in vivo reaction velocity: 31P NMR surface coil studies in brain, heart and skeletal muscle of the living rat. Biochemistry. 1987;26:6083-6090.[Medline] [Order article via Infotrieve]

21. Polimeni PI. Measurement of myocardial electrolyte distributions. Tech Life Cardiovasc Physiol. 1984;317:1-34.

22. Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith G. Regional myocardial metabolism of high energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med. 1990;323:1593-1600.[Abstract]

23. Regitz V, Fleck E. Myocardial adenine nucleotide concentrations and myocardial norepinephrine content in patients with heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol. 1992;69:1574-1580.[Medline] [Order article via Infotrieve]

24. Bashore TM, Magorien DJ, Letterio J, Shaffer P, Unverferth DV. Histologic and biochemical correlates of left ventricular chamber dynamics in man. J Am Coll Cardiol. 1987;9:734-742.[Abstract]

25. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790-804.[Abstract/Free Full Text]

26. Waldenstrom A, Martinussen HJ, Kock J, Ronquist G, Hultman J. Parasympathetic muscarinic stimulation limits noradrenaline induced myocardial creatine kinase release: a study in the isolated perfused working rat heart. Scand J Clin Lab Invest. 1994;54:615-621.[Medline] [Order article via Infotrieve]

27. Chapados RA, Gruver EJ, Ingwall JS, Marsh JD, Gwathmey JK. Chronic administration of cardiovascular drugs: altered energetics and transmembrane signaling. Am J Physiol. 1992;263:H1576-H1586.[Abstract/Free Full Text]

28. Cohn JN, Levine B, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.[Abstract]

29. Anderson PAW, Malouf NN, Oakeley AE, Pagani ED, Allen PD. Troponin T isoform expression in humans: a comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circ Res. 1991;69:1226-1233.[Abstract/Free Full Text]

30. Younes A, Schneider JM, Bercovici J, Swynghedauw B. Redistribution of creatine kinase isoenzymes in chronically overloaded myocardium. Cardiovasc Res. 1984;19:15-19.

31. Sylven C, Lin L, Kallner A, Sotonyi E, Somogy E, Jansson E. Dynamics of creatine kinase shuttle enzymes in the human heart. Eur J Clin Invest. 1991;21:350-354.[Medline] [Order article via Infotrieve]

32. van der Laarse A, Hollaar L, Kok SW, van den Eijnde S, Souverijn JHM, Hoedemaeker PJ, Bruschke AVG. Myocardial creatine kinase-MB concentration in normal and explanted human hearts and released from hearts of patients with acute myocardial infarction. Clin Physiol Biochem. 1992;9:11-17.[Medline] [Order article via Infotrieve]

33. Metha HB, Popovich BK, Dillman WK. Ischemia induces changes in the level of mRNAs coding for stress protein 71 and creatine kinase M. Circ Res. 1988;63:512-517.[Abstract/Free Full Text]

34. Sharkey SW, Elsperger LM, Markami M, Apple FS. Canine myocardial creatine kinase isoenzyme response to coronary artery occlusion. Am J Physiol. 1989;256:H508-H514.[Abstract/Free Full Text]

35. Reiss N, Kaye AM. Identification of the major component of the estrogen-induced protein of rat uterus as the BB isozyme of creatine kinase. J Biol Chem. 1981;256:5741-5749.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
CirculationHome page
G. Michels, I. F. Khan, J. Endres-Becker, D. Rottlaender, S. Herzig, A. Ruhparwar, T. Wahlers, and U. C. Hoppe
Regulation of the Human Cardiac Mitochondrial Ca2+ Uptake by 2 Different Voltage-Gated Ca2+ Channels
Circulation, May 12, 2009; 119(18): 2435 - 2443.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. S. Ingwall
Energy metabolism in heart failure and remodelling
Cardiovasc Res, February 15, 2009; 81(3): 412 - 419.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
F. Joubert, J. R. Wilding, D. Fortin, V. Domergue-Dupont, M. Novotova, R. Ventura-Clapier, and V. Veksler
Local energetic regulation of sarcoplasmic and myosin ATPase is differently impaired in rats with heart failure
J. Physiol., November 1, 2008; 586(21): 5181 - 5192.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. J. Eisen
Exercise Training and Myocardial Energetics in Patients With Heart Failure: When More Is Less
J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1892 - 1895.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. Pinz, S. E. Ostroy, K. Hoyer, H. Osinska, J. Robbins, J. D. Molkentin, and J. S. Ingwall
Calcineurin-induced energy wasting in a transgenic mouse model of heart failure
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1459 - H1466.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
L. V. Zingman, A. E. Alekseev, D. M. Hodgson-Zingman, and A. Terzic
ATP-sensitive potassium channels: metabolic sensing and cardioprotection
J Appl Physiol, November 1, 2007; 103(5): 1888 - 1893.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
O. J. Kemi, M. A. Hoydal, P. M. Haram, A. Garnier, D. Fortin, R. Ventura-Clapier, and O. Ellingsen
Exercise training restores aerobic capacity and energy transfer systems in heart failure treated with losartan
Cardiovasc Res, October 1, 2007; 76(1): 91 - 99.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. Neubauer
The Failing Heart -- An Engine Out of Fuel
N. Engl. J. Med., March 15, 2007; 356(11): 1140 - 1151.
[Full Text] [PDF]


Home page
Asian Cardiovasc. Thorac. Ann.Home page
Y J. Woo, T. J Grand, G. P Liao, and C. M Panlilio
Off-pump revascularization for significant left ventricular dysfunction.
Asian Cardiovasc Thorac Ann, August 1, 2006; 14(4): 306 - 309.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. E. Cullen, A. H.Y. Yuen, L. E. Felkin, R. T. Smolenski, J. L. Hall, S. Grindle, L. W. Miller, E. J. Birks, M. H. Yacoub, and P. J.R. Barton
Myocardial Expression of the Arginine:Glycine Amidinotransferase Gene Is Elevated in Heart Failure and Normalized After Recovery: Potential Implications for Local Creatine Synthesis
Circulation, July 4, 2006; 114(1_suppl): I-16 - I-20.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
G. Fragasso, G. Perseghin, F. De Cobelli, A. Esposito, A. Palloshi, G. Lattuada, P. Scifo, G. Calori, A. Del Maschio, and A. Margonato
Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure
Eur. Heart J., April 2, 2006; 27(8): 942 - 948.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
V. Saks, P. Dzeja, U. Schlattner, M. Vendelin, A. Terzic, and T. Wallimann
Cardiac system bioenergetics: metabolic basis of the Frank-Starling law
J. Physiol., March 1, 2006; 571(2): 253 - 273.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Wallis, C. A. Lygate, A. Fischer, M. ten Hove, J. E. Schneider, L. Sebag-Montefiore, D. Dawson, K. Hulbert, W. Zhang, M. H. Zhang, et al.
Supranormal Myocardial Creatine and Phosphocreatine Concentrations Lead to Cardiac Hypertrophy and Heart Failure: Insights From Creatine Transporter-Overexpressing Transgenic Mice
Circulation, November 15, 2005; 112(20): 3131 - 3139.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
Y. J. Woo, T. J. Grand, M. F. Berry, P. Atluri, M. A. Moise, V. M. Hsu, J. Cohen, O. Fisher, J. Burdick, M. Taylor, et al.
Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy
J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 321 - 329.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. ten Hove, C. A. Lygate, A. Fischer, J. E. Schneider, A. E. Sang, K. Hulbert, L. Sebag-Montefiore, H. Watkins, K. Clarke, D. Isbrandt, et al.
Reduced Inotropic Reserve and Increased Susceptibility to Cardiac Ischemia/Reperfusion Injury in Phosphocreatine-Deficient Guanidinoacetate-N-Methyltransferase-Knockout Mice
Circulation, May 17, 2005; 111(19): 2477 - 2485.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. G. Weiss, G. Gerstenblith, and P. A. Bottomley
ATP flux through creatine kinase in the normal, stressed, and failing human heart
PNAS, January 18, 2005; 102(3): 808 - 813.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. S. Ingwall and R. G. Weiss
Is the Failing Heart Energy Starved?: On Using Chemical Energy to Support Cardiac Function
Circ. Res., July 23, 2004; 95(2): 135 - 145.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
R. Ventura-Clapier, A. Garnier, and V. Veksler
Energy metabolism in heart failure
J. Physiol., February 15, 2004; 555(1): 1 - 13.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
I. Nakae, K. Mitsunami, T. Omura, T. Yabe, T. Tsutamoto, S. Matsuo, M. Takahashi, S. Morikawa, T. Inubushi, Y. Nakamura, et al.
Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy
J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1587 - 1593.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
O. Ogut and F. V. Brozovich
Creatine Phosphate Consumption and the Actomyosin Crossbridge Cycle in Cardiac Muscles
Circ. Res., July 11, 2003; 93(1): 54 - 60.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. J. Harrison, M. H. van Wijhe, B. de Groot, F. J. Dijk, L. A. Gustafson, and J. H. G. M. van Beek
Glycolytic buffering affects cardiac bioenergetic signaling and contractile reserve similar to creatine kinase
Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H883 - H890.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Wendt, U. Schlattner, and T. Wallimann
Differential Effects of Peroxynitrite on Human Mitochondrial Creatine Kinase Isoenzymes. INACTIVATION, OCTAMER DESTABILIZATION, AND IDENTIFICATION OF INVOLVED RESIDUES
J. Biol. Chem., January 3, 2003; 278(2): 1125 - 1130.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Beer, T. Seyfarth, J.o. Sandstede, W. Landschutz, C. Lipke, H. Kostler, M. von Kienlin, K. Harre, D. Hahn, and S. Neubauer
Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with 31P-SLOOP magnetic resonance spectroscopy
J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1267 - 1274.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
R. Ventura-Clapier, E. De Sousa, and V. Veksler
Metabolic Myopathy in Heart Failure
Physiology, October 1, 2002; 17(5): 191 - 196.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. van der Laarse
Hypothesis: troponin degradation is one of the factors responsible for deterioration of left ventricular function in heart failure
Cardiovasc Res, October 1, 2002; 56(1): 8 - 14.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Spindler, R. Niebler, H. Remkes, M. Horn, T. Lanz, and S. Neubauer
Mitochondrial creatine kinase is critically necessary for normal myocardial high-energy phosphate metabolism
Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H680 - H687.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. J. Park, J. Zhang, Y. Ye, S. Ormaza, P. Liang, A. J. Bank, L. W. Miller, and R. J. Bache
Myocardial creatine kinase expression after left ventricular assist device support
J. Am. Coll. Cardiol., June 5, 2002; 39(11): 1773 - 1779.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Joubert, J.-L. Mazet, P. Mateo, and J. A. Hoerter
31P NMR Detection of Subcellular Creatine Kinase Fluxes in the Perfused Rat Heart. CONTRACTILITY MODIFIES ENERGY TRANSFER PATHWAYS
J. Biol. Chem., May 17, 2002; 277(21): 18469 - 18476.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
T. M. Welsh, G. D. Kukes, and L. M. Sandweiss
Differences of Creatine Kinase MB and Cardiac Troponin I Concentrations in Normal and Diseased Human Myocardium
Ann. Clin. Lab. Sci., January 1, 2002; 32(1): 44 - 49.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. Mettauer, J. Zoll, H. Sanchez, E. Lampert, F. Ribera, V. Veksler, X. Bigard, P. Mateo, E. Epailly, J. Lonsdorfer, et al.
Oxidative capacity of skeletal muscle in heart failure patients versus sedentary or active control subjects
J. Am. Coll. Cardiol., October 1, 2001; 38(4): 947 - 954.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M.-L. L. Boumans, J. H.C. Diris, M. Nap, A. M.M. Muijtjens, J. G. Maessen, M. P. van Dieijen-Visser, and W. T. Hermens
Creatine Kinase Isoenzyme MB (CKMB) Controversy: Perimortal Tissue Acidosis May Explain the Absence of CKMB in Myocardium at Autopsy
Clin. Chem., September 1, 2001; 47(9): 1733 - 1735.
[Full Text] [PDF]


Home page
CirculationHome page
M. J. Mihm, F. Yu, C. A. Carnes, P. J. Reiser, P. M. McCarthy, D. R. Van Wagoner, and J. A. Bauer
Impaired Myofibrillar Energetics and Oxidative Injury During Human Atrial Fibrillation
Circulation, July 10, 2001; 104(2): 174 - 180.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Tian and E. D. Abel
Responses of GLUT4-Deficient Hearts to Ischemia Underscore the Importance of Glycolysis
Circulation, June 19, 2001; 103(24): 2961 - 2966.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Y. Ye, G. Gong, K. Ochiai, J. Liu, and J. Zhang
High-Energy Phosphate Metabolism and Creatine Kinase in Failing Hearts : A New Porcine Model
Circulation, March 20, 2001; 103(11): 1570 - 1576.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. J. Mihm, C. M. Coyle, B. L. Schanbacher, D. M. Weinstein, and J. A. Bauer
Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure
Cardiovasc Res, March 1, 2001; 49(4): 798 - 807.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. G. Crilley, E. A. Boehm, B. Rajagopalan, A. M. Blamire, P. Styles, F. Muntoni, D. Hilton-Jones, and K. Clarke
Magnetic resonance spectroscopy evidence of abnormal cardiac energetics in Xp21 muscular dystrophy
J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1953 - 1958.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. P. Chacko, F. Aresta, S. M. Chacko, and R. G. Weiss
MRI/MRS assessment of in vivo murine cardiac metabolism, morphology, and function at physiological heart rates
Am J Physiol Heart Circ Physiol, November 1, 2000; 279(5): H2218 - H2224.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. De Sousa, V. Veksler, X. Bigard, P. Mateo, and R. Ventura-Clapier
Heart Failure Affects Mitochondrial but Not Myofibrillar Intrinsic Properties of Skeletal Muscle
Circulation, October 10, 2000; 102(15): 1847 - 1853.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. H. Lorell and B. A. Carabello
Left Ventricular Hypertrophy : Pathogenesis, Detection, and Prognosis
Circulation, July 25, 2000; 102(4): 470 - 479.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
X.-H. Ning, J. Zhang, J. Liu, Y. Ye, S.-H. Chen, A. H. L. From, R. J. Bache, and M. A. Portman
Signaling and expression for mitochondrial membrane proteins during left ventricular remodeling and contractile failure after myocardial infarction
J. Am. Coll. Cardiol., July 1, 2000; 36(1): 282 - 287.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. Wyss and R. Kaddurah-Daouk
Creatine and Creatinine Metabolism
Physiol Rev, July 1, 2000; 80(3): 1107 - 1213.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. D. Prabhu and G. L. Freeman
Altered LV inotropic reserve and mechanoenergetics early in the development of heart failure
Am J Physiol Heart Circ Physiol, March 1, 2000; 278(3): H698 - H705.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. I. Miyamoto, F. del Monte, U. Schmidt, T. S. DiSalvo, Z. B. Kang, T. Matsui, J. L. Guerrero, J. K. Gwathmey, A. Rosenzweig, and R. J. Hajjar
Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure
PNAS, January 18, 2000; 97(2): 793 - 798.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Hugel, M. Horn, M. de Groot, H. Remkes, C. Dienesch, K. Hu, G. Ertl, and S. Neubauer
Effects of ACE inhibition and beta -receptor blockade on energy metabolism in rats postmyocardial infarction
Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2167 - H2175.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Neubauer, H. Remkes, M. Spindler, M. Horn, F. Wiesmann, J. Prestle, B. Walzel, G. Ertl, G. Hasenfuss, and T. Wallimann
Downregulation of the Na+-Creatine Cotransporter in Failing Human Myocardium and in Experimental Heart Failure
Circulation, November 2, 1999; 100(18): 1847 - 1850.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. J.M. de Groot, K.W. H. Wodzig, M. L. Simoons, J. F.C. Glatz, and W. Th. Hermens
Measurement of myocardial infarct size from plasma fatty acid-binding protein or myoglobin, using individually estimated clearance rates
Cardiovasc Res, November 1, 1999; 44(2): 315 - 324.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
E. De Sousa, V. Veksler, A. Minajeva, A. Kaasik, P. Mateo, E. Mayoux, J. Hoerter, X. Bigard, B. Serrurier, and R. Ventura-Clapier
Subcellular Creatine Kinase Alterations : Implications in Heart Failure
Circ. Res., July 9, 1999; 85(1): 68 - 76.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Horn, H. Remkes, C. Dienesch, K. Hu, G. Ertl, and S. Neubauer
Chronic high-dose creatine feeding does not attenuate left ventricular remodeling in rat hearts post-myocardial infarction
Cardiovasc Res, July 1, 1999; 43(1): 117 - 124.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
P. P. Dzeja, K. T. Vitkevicius, M. M. Redfield, J. C. Burnett, and A. Terzic
Adenylate Kinase–Catalyzed Phosphotransfer in the Myocardium : Increased Contribution in Heart Failure
Circ. Res., May 28, 1999; 84(10): 1137 - 1143.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. J. Harrison, M. H. van Wijhe, B. de Groot, F. J. Dijk, and J. H. G. M. van Beek
CK inhibition accelerates transcytosolic energy signaling during rapid workload steps in isolated rabbit hearts
Am J Physiol Heart Circ Physiol, January 1, 1999; 276(1): H134 - H140.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Kameyama, Z. Chen, S. P. Bell, P. VanBuren, D. Maughan, and M. M. LeWinter
Mechanoenergetic Alterations During the Transition From Cardiac Hypertrophy to Failure in Dahl Salt-Sensitive Rats
Circulation, December 22, 1998; 98(25): 2919 - 2929.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. W. Saupe, M. Spindler, R. Tian, and J. S. Ingwall
Impaired Cardiac Energetics in Mice Lacking Muscle-Specific Isoenzymes of Creatine Kinase
Circ. Res., May 4, 1998; 82(8): 898 - 907.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Neubauer, M. Horn, M. Cramer, K. Harre, J. B. Newell, W. Peters, T. Pabst, G. Ertl, D. Hahn, J. S. Ingwall, et al.
Myocardial Phosphocreatine-to-ATP Ratio Is a Predictor of Mortality in Patients With Dilated Cardiomyopathy
Circulation, October 7, 1997; 96(7): 2190 - 2196.
[Abstract] [Full Text]


Home page
CirculationHome page
R. Tian, L. Nascimben, J. S. Ingwall, and B. H. Lorell
Failure to Maintain a Low ADP Concentration Impairs Diastolic Function in Hypertrophied Rat Hearts
Circulation, August 19, 1997; 96(4): 1313 - 1319.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
K. W. Saupe, M. Spindler, J. C. A. Hopkins, W. Shen, and J. S. Ingwall
Kinetic, Thermodynamic, and Developmental Consequences of Deleting Creatine Kinase Isoenzymes from the Heart. REACTION KINETICS OF THE CREATINE KINASE ISOENZYMES IN THE INTACT HEART
J. Biol. Chem., June 23, 2000; 275(26): 19742 - 19746.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Pucar, E. Janssen, P. P. Dzeja, N. Juranic, S. Macura, B. Wieringa, and A. Terzic
Compromised Energetics in the Adenylate Kinase AK1 Gene Knockout Heart under Metabolic Stress
J. Biol. Chem., December 22, 2000; 275(52): 41424 - 41429.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Pucar, P. P. Dzeja, P. Bast, N. Juranic, S. Macura, and A. Terzic
Cellular Energetics in the Preconditioned State. PROTECTIVE ROLE FOR PHOSPHOTRANSFER REACTIONS CAPTURED BY 18O-ASSISTED 31P NMR
J. Biol. Chem., November 21, 2001; 276(48): 44812 - 44819.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nascimben, L.
Right arrow Articles by Allen, P.D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nascimben, L.
Right arrow Articles by Allen, P.D.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Heart Failure